Monopar Therapeutics is an emerging biopharmaceutical company focused on developing innovative drug combinations to improve clinical outcomes in advanced cancer. Monopar currently has three compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a mucoadhesive local anti-inflammatory tablet for the prevention and treatment of severe oral mucositis (SOM) in head and neck cancer patients; MNPR-201 (formerly GPX-150), a proprietary analog of doxorubicin engineered specifically to retain the anticancer activity of doxorubicin while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR), for the treatment of advanced solid cancers. MNPR-101 (huATN-658) is being developed in collaboration with Cancer Research UK. Monopar’s team is located in San Francisco, CA, Seattle, WA, and Chicago, IL.
Licensing, developing and commercializing transformative Oncology therapeutics
Multiple factors drive our passion for Oncology
The numbers behind our research define its opportunities
Validive (clonidine MBT) is a Phase 3 asset to prevent severe oral mucositis (SOM) in patients undergoing radiation treatment for head and neck cancer. MNPR-201 (formerly GPX-150) is a Phase II drug that has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing toxic effects on the heart, allowing it to be used more safely and effectively when combined with other cancer drugs in patients with advanced cancer. MNPR-101 (huATN-658) is a humanized monoclonal antibody targeting urokinase plasminogen activator receptor (uPAR) positive solid tumors with development funded through Phase 1b via a partnership with Cancer Research UK.